Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) has provided an announcement.
On October 15, 2025, Shuttle Pharmaceuticals Holdings, Inc. received a termination notice from Theradex Systems, Inc. regarding their master agreement, leading to a settlement where Shuttle Pharmaceuticals will pay $300,000 to Theradex to settle outstanding liabilities. Consequently, Shuttle Pharmaceuticals has decided to discontinue its clinical trials of Ropidoxuridine, expecting to incur additional expenses related to trial closeout activities, with most charges anticipated in the fourth quarter of 2025.
Spark’s Take on SHPH Stock
According to Spark, TipRanks’ AI Analyst, SHPH is a Underperform.
Shuttle Pharmaceuticals Holdings, Inc. faces significant financial challenges with no revenue and ongoing cash burn. Technical indicators show bearish trends, and valuation metrics highlight the company’s unprofitability. While recent corporate activities offer potential strategic benefits, they also add financial strain and governance complexities, leading to an overall low stock score.
To see Spark’s full report on SHPH stock, click here.
More about Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. operates in the pharmaceutical industry, focusing on the development of drugs and therapies. The company is involved in clinical trials and research, particularly in the area of cancer treatment.
Average Trading Volume: 233,292
Technical Sentiment Signal: Sell
Current Market Cap: $3.17M
For a thorough assessment of SHPH stock, go to TipRanks’ Stock Analysis page.